Evoke SCS System Shows Positive 36-Month Results, FDA Lifts Hold on FORTIS, Complete Response Letter Issued for Donanemab
Neurology News Network for the week ending January 28, 2023. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
Welcome to this special edition of Neurology News Network. I’m Marco Meglio.
Presented at the 2023 North American Neuromodulation Society (NANS) annual meeting, new 36-month
Recently, the
The FDA issued a complete response letter to Eli Lilly for its investigational antiamyloid therapy donanemab, a humanized IgG1 monoclonal antibody, for the treatment of symptomatic Alzheimer disease (AD). A lack of participants who received continuous treatment with donanemab for at least 12 months was the reason for the decision, with no other noted concerns. In its response letter, the FDA requested the company provide data from at least 100 patients who have received a minimum of 12 months of continuous treatment with donanemab. The phase 2 TRAILBLAZER-ALZ study, which served as the basis for the biologics license application of donanemab, included more than 100 patients; however, it was designed so that patients would complete the treatment course once they reached a predefined level of amyloid plaque clearance.
For more direct access to expert insight, head to NeurologyLive.com. This has been Neurology News Network. Thanks for watching.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.